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Background: The University Hospital of Liege is a 925-bed facility located on four different places. In 2004, all the wards were equipped with Accu-check Inform glucose meters (Roche Diagnostics, Mannheim,Germany), a near-patient device used to monitor blood glucose levels. In 2010, we moved to the Accu-check Inform II with the Accu-check Inform II strips. These strips do not present interference in the presence of maltose anymore, which makes them suitable for use in peritoneal dialysis. We have now 105 Informs II and are yearly running 350.000 strips. A two-levelled quality control (QC) needs to be tested every day by the nurses and is mandatory for the use of the meters. We also run an external proficiency test four times a year. Nevertheless, one of the major problems with these devices is the analytical validation of the meters and of the strips before use in the wards. We present here our experience in validating the Informs and strips. 
Methods: First, we validated the Informs: each of the 6 vials contained in the Roche linearity kit (with increasing concentrations of glucose, from approximately 25 to 550 mg/dL) was run in simplicate. Next, the two-levelled QC were run in triplicate for 5 different days to evaluate the imprecision and the relative bias compared to the mean of the values. Then, we calculated the total error as TE=2.33*Imprecision(%)+|Bias|(%). A TE<14% was expected. Three Informs were then randomly selected and we assayed in triplicates, on five different days and on two different Accu-check Inform II strips lots, the 6 vials of the linearity kit. Finally, a comparison with the glucose electrode of the RapidLab 865 (Siemens, Deerfield, IL) on the three-levelled internal QC of the blood-gas analyzer was performed. We used the e-noval software to establish the accuracy profiles and we settled the tolerance limit at 10%, according to the American Association of Diabetes.    
Results: The total error was lower than 14% for all meters (mean: 6.9 and 5.7% at respectively 0.49 and 2.91 mg/dL). With the linearity kit, the accuracy profile built with the predictive tolerance interval method shows that, on average, 95% of the future results that will be generated will be included in the computed tolerance intervals of 10% in the 25-550 mg/dL studied range. With the internal QC of the Rapidlab, taking the expected mean obtained with the electrode as the reference, 95% of results are also included in the computed tolerance intervals of 10% in the 50-200 mg/dL studied range.    
Conclusions: we have completely validated the Accu-check Inform II meters and strips. Our results show that, on the different controls, we are in confidence for value ranging from 25 to 550 mg/dL, which is an important improvement for the method. Even if a true “patient” validation remains important, it is cumbersome and can not be proposed for the evaluation of all the meters and different strips lots. Our approach is pragmatic and allows us to certify the quality of the material before use in the wards.
 
 

